Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S R Schwid

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Neurology|May 2, 2007
Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosisE R Dorsey, J P Thompson, K Noyes, et al.
Neurology|April 1, 1997
Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosisS R Schwid, M D Petrie, M P McDermott, et al.
Archives of Neurology|April 6, 1999
Neuropsychologic status in multiple sclerosis after treatment with glatiramerA Weinstein, S R Schwid, R B Schiffer, et al.
Neurology|July 22, 2011
Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based studyK Noyes, A Bajorska, A Chappel, et al.
Neurology|September 17, 1999
Quantitative assessment of motor fatigue and strength in MSS R Schwid, C A Thornton, S Pandya, et al.
Neurology|August 2, 2008
Dose comparison trial of sustained-release fampridine in multiple sclerosisA D Goodman, T R Brown, J A Cohen, et al.
Neurology|December 31, 1997
The measurement of ambulatory impairment in multiple sclerosisS R Schwid, A D Goodman, D H Mattson, et al.
Neurology|January 3, 2001
Are quantitative functional measures more sensitive to worsening MS than traditional measures?S R Schwid, A D Goodman, B R Apatoff, et al.
Neurology|April 27, 2011
Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosisL B Krupp, C Christodoulou, P Melville, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2009
Assessing disability progression with the Multiple Sclerosis Functional CompositeR A Rudick, C H Polman, J A Cohen, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Neurology|May 2, 2007
Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosisE R Dorsey, J P Thompson, K Noyes, et al.
Neurology|April 1, 1997
Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosisS R Schwid, M D Petrie, M P McDermott, et al.
Archives of Neurology|April 6, 1999
Neuropsychologic status in multiple sclerosis after treatment with glatiramerA Weinstein, S R Schwid, R B Schiffer, et al.
Neurology|July 22, 2011
Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based studyK Noyes, A Bajorska, A Chappel, et al.
Neurology|September 17, 1999
Quantitative assessment of motor fatigue and strength in MSS R Schwid, C A Thornton, S Pandya, et al.
Neurology|August 2, 2008
Dose comparison trial of sustained-release fampridine in multiple sclerosisA D Goodman, T R Brown, J A Cohen, et al.
Neurology|December 31, 1997
The measurement of ambulatory impairment in multiple sclerosisS R Schwid, A D Goodman, D H Mattson, et al.
Neurology|January 3, 2001
Are quantitative functional measures more sensitive to worsening MS than traditional measures?S R Schwid, A D Goodman, B R Apatoff, et al.
Neurology|April 27, 2011
Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosisL B Krupp, C Christodoulou, P Melville, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2009
Assessing disability progression with the Multiple Sclerosis Functional CompositeR A Rudick, C H Polman, J A Cohen, et al.
Pageof 3